

COPD WORKING GROUP ERS Conference 2018

Minutes

Meeting location	Room 7.3F Paris Expo Porte de Versailles 1 Place de la Porte de Versailles, 75015 Paris, France	
Meeting date	Sunday 16 September 2018	
Meeting time	9:00 - 10:00 am	
Lead	Marc Miravittles	
Attendees	Ron Dandurand Jaco Voorham Nicolas Roche Keith Allan	Miriam Barrecheguren Bernardino Alcazar Naomi Launders Michael Walker Kathryn Brown
Objective	<ul style="list-style-type: none"> • Provide an update on current projects • Prioritise ideas for future projects and develop a plan for implementing one of these projects. • Identify new project ideas in the field of COPD 	

1	<p>Update on current projects</p> <ul style="list-style-type: none"> • Validation of the concept of control of COPD in clinical practice. <p>Marc presented the results of the study so far. It was agreed that this was an interesting study and that the study sites were enthusiastic and engaged. An abstract should be submitted for ERS 2019.</p> <p>Action: REG to ensure an abstract is submitted for ERS 2019.</p> <p>It was suggested that this project could be extended for another five years to answer other questions as it is a well characterized cohort, pending funding from the trial sponsor.</p> <p>Testing the thresholds for variables to find the most accurate was suggested, both in the existing cohort and others.</p> <ul style="list-style-type: none"> • Pilot study - Modern epidemiology of alpha-1-antitrypsin deficiency (AATD) in the UK. (PI Joan Soriano). <p>The follow up to this study was discussed, although the lack of licensed treatment in the UK may make funding this study difficult. Need to determine if there would be enough cases in the database to ensure a well powered study when looking at</p>
----------	---

	<p>stratifying the data. Spain, Italy and Germany may be a better population to look at. REG to contact Prof. Claus Volgemeier in Germany, author of the GOLD guidelines.</p>
<p>2</p>	<p>Plans for future projects</p> <ul style="list-style-type: none"> • Implications of ICS withdrawal in the real-life management of COPD-Real-life WISDOM. (PI Marc Miravittles) <p>This was thought to still be a very relevant study. It was mentioned that others may be doing similar and we may be able to coordinate efforts. A call with MM, REG and funders was suggested.</p> <p>Action: REG to follow up with MM.</p> <ul style="list-style-type: none"> • Claims-based validation of a UK COPD Risk Prediction model. <p>This is on hold, pending the asthma risk prediction validation work.</p> <p>The other projects listed were decided to be out of date and no longer of relevance.</p>
<p>3</p>	<ul style="list-style-type: none"> • The possibility of the device used impacting outcomes was discussed briefly, though Jaco reported he had looked at this and there wasn't much difference. • Risk stratification based on the time to first exacerbation and admission was suggested as an area of further research. How do outcomes differ depending on whether a patient has e.g. 1 exacerbation or 1 hospitalization? Also – does the use of therapeutics predict better outcomes?